New Evidence Supports Chromogenic Assays After Hemophilia A Gene Therapy – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Flora Peyvandi et al, adding:
”Correlation between Factor VIII chromogenic activity and antigen levels in patients treated with adeno-associated virus 5-mediated gene therapy for hemophilia A
In four patients with severe hemophilia A, FVIII antigen levels closely matched chromogenic assay results after gene therapy, supporting it as the preferred monitoring method.”
Title: Correlation between Factor VIII chromogenic activity and antigen levels in patients treated with adeno-associated virus 5-mediated gene therapy for hemophilia A
Authors: Flora Peyvandi, Isabella Garagiola, Novembrino Cristina, Lucia Schiavone, Massimo Boscolo-Anzoletti, Alessandro Ciavarella, Vincenzo La Mura
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 3, 2026, 05:50Jacopo Parizzi: Roche’s Non-Malignant Hematology Team Is Looking Ahead to 2027
-
Jul 3, 2026, 05:25Brian A Beh: A New Approach from The George Institute for Global Health Could Transform Stroke Care Before Hospital Arrival
-
Jul 3, 2026, 05:22Deirdre Finnigan: New Insights into Red Blood Cell Biomechanics in Cancer-Associated Anemia
-
Jul 3, 2026, 05:15Danielle Boyle: Collaboration Across Borders Is Helping Shape the Future of ITP Care
-
Jul 3, 2026, 05:05Claire McIvor: One Year at the Stroke Association and Grateful for a Workplace That Made It Possible
-
Jul 2, 2026, 23:11Michael Makris: Join The Cancer Associated Thrombosis Workshop at ISTH 2026
-
Jul 2, 2026, 21:54Rob Maloney: Rare Disease Requires Relational Care
-
Jul 2, 2026, 21:53Quintijn Bonnez: How ADAMTS13 Conformation May Predict Early Relapse and Guide Pre-Emptive Therapy
-
Jul 2, 2026, 21:52Emina Curic: Improving the Understanding of Factor V Leiden in Everyday Clinical Practice